首页> 外文期刊>Pharmacogenetics and genomics >Functional assessment of genetic variants located in the promoter of SHP1 (NR0B2)
【24h】

Functional assessment of genetic variants located in the promoter of SHP1 (NR0B2)

机译:Shp1启动子遗传变异的功能评估(NR0B2)

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Small heterodimer partner 1 (SHP1, NR0B2) is a member of the superfamily of nuclear receptors (NRs). Even if this orphan receptor, unlike other NRs, lacks the DNA-binding domain, it is capable of regulating transcription by repressing the activity of other NRs by direct protein-protein interaction. Accordingly, SHP1 is part of negative feedback loops of the transcriptional regulation of genes involved in drug metabolism and various metabolic pathways including bile acid and glucose homeostasis. Although it is known that several interacting partners of SHP1 also modulate its expression, there is little information about genetic variability of this regulatory mechanism. Our study aimed to identify genetic variants in the NR0B2 promoter region and to determine their impact on NR0B2 transcription. For this, DNA samples originating from 119 participants of the population-based cohort Study of Health in Pomerania were analyzed by Sanger sequencing revealing four genetic variants: NR0B2: c.-594T > C (rs71636795), NR0B2: c.-414G > C (newly identified), NR0B2: c.-423C > T (rs78182695), and NR0B2: c.-224delCTGA (rs145613139) localized in the 5' untranslated region of NR0B2. The impact of these variants on transactivation of the NR0B2 promoter by NRs known to be regulators of SHP1 expression (hepatocyte nuclear factor 4a, liver receptor homolog-1, and farnesoid X receptor) was assessed in a cell-based reporter gene assay, showing that transactivation by hepatocyte nuclear factor 4a and liver receptor homolog-1 was significantly decreased in the presence of the genetic variant NR0B2: c.-594T>C, even though this effect was cell specific. However, SHP1 mRNA expression in a small collection of human kidney samples was not affected by these genetic variants. Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved.
机译:小异二聚体合作伙伴1(SHP1,NR0B2)是核受体超家族(NRS)的成员。即使这种孤儿受体与其他NR不同,缺乏DNA结合结构域,它也能够通过直接蛋白质 - 蛋白质相互作用压制其他NRS的活性来调节转录。因此,SHP1是参与药物代谢的基因的转录调节的负反馈回路的一部分,以及包括胆汁酸和葡萄糖稳态的各种代谢途径。虽然已知SHP1的几个相互作用的伴侣也调节其表达,但是关于这种调节机制的遗传变异性的信息很少。我们的研究旨在鉴定NR0B2启动子区的遗传变异,并确定它们对NR0B2转录的影响。为此,通过Sanger测序分析了来自Pomerania的基于人口群体的119名参与者的DNA样本,揭示了四种遗传变异:NR0B2:C.-594T> C(RS71636795),NR0B2:C.-414G> C. (新鉴定),NR0B2:C.-423C> T(RS78182695)和NR0B2:C.-224DelctGA(RS145613139)定位在NR0B2的5'未翻译区域中。在基于细胞的报告基因测定中评估了已知的NRS对SHP1表达(肝细胞核因子4A,肝受体同源物同源物和法呢X受体)的调节剂的NR0B2启动子转移的影响。在遗传变异NR0B2:C.-594T> C的情况下,肝细胞核因子4a和肝受体同源物-1的反式激活显着降低,即使这种效果是特异性的这种效果。然而,在一小部分人肾样本中的SHP1 mRNA表达不受这些遗传变异的影响。版权所有(C)2017 Wolters Kluwer Health,Inc。保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号